- Citations, last 5 years
- 38
- Works, last 5 years
- 3
- h-index
- 22
- Scientists listed
- 0
- Grants since 2016
- 21
Grants received
2025–2027 · research · R43
Development of a metabolomics enabled AI/ML platform for discovery of new treatments to enhance drug sensitivity in cancer
Bernard Bloem · Sinopia Biosciences (United States) · funded by National Institutes of Health
2025–2026 · research · R43
Development of neural network models to enable efficient metabolomic characterization of compound libraries for data-driven drug discovery
Bernard Bloem · Sinopia Biosciences (United States) · funded by National Institutes of Health
2024–2026 · research · R44
Preclinical assessment of a novel compound for treating radiation-induced oral mucositis
Colton Joseph Lloyd · Sinopia Biosciences (United States) · funded by National Institutes of Health
2024 · research · Parkinson’s Disease Therapeutics Pipeline Program
First-in-human Phase 1a Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending doses of SB-0110 after Oral Administration in Healthy Subjects
Aarash Bordbar · Sinopia Biosciences (United States) · funded by Michael J. Fox Foundation for Parkinson's Research
2024–2025 · research · R43
Development and validation of data standards and computational methods for large scale metabolomics data analysis for data driven drug discovery
Bernard Bloem · Sinopia Biosciences (United States) · funded by National Institutes of Health
2024–2026 · research · R44
Preclinical assessment of a novel compound for treating radiation-induced oral mucositis
Colton Joseph Lloyd · Sinopia Biosciences (United States) · funded by National Institutes of Health
2024–2026 · research · R44
Preclinical assessment of a novel compound for treating radiation-induced oral mucositis
Colton Joseph Lloyd · Sinopia Biosciences (United States) · funded by National Institutes of Health
2023–2025 · research · R44
Preclinical development of a novel therapeutic for Parkinson's disease
Aarash Bordbar · Sinopia Biosciences (United States) · funded by National Institutes of Health
2022–2024 · research · R43
Preclinical assessment of a novel compound for treating radiation-induced oral mucositis
Colton Joseph Lloyd · Sinopia Biosciences (United States) · funded by National Institutes of Health
2021–2025 · research · R44
Preclinical development of a novel therapeutic for Parkinson's disease
Aarash Bordbar · Sinopia Biosciences (United States) · funded by National Institutes of Health
2021–2023 · research · R44
Preclinical development of a novel therapeutic for Parkinson's disease
Aarash Bordbar · Sinopia Biosciences (United States) · funded by National Institutes of Health
2021–2025 · research · R44
Preclinical development of a novel therapeutic for Parkinson's disease
Aarash Bordbar · Sinopia Biosciences (United States) · funded by National Institutes of Health
2019 · research · Therapeutic Pipeline Program
Study of a Levodopa Adjunctive Therapeutic without Dyskinesia Liability
Aarash Bordbar · Sinopia Biosciences (United States) · funded by Michael J. Fox Foundation for Parkinson's Research
2019–2020 · research · R43
Improving safety and efficacy of platelet pathogen inactivation techniques through systems biology
Aarash Bordbar · Sinopia Biosciences (United States) · funded by National Institutes of Health
2018–2023 · research · R44
Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery
Aarash Bordbar · Sinopia Biosciences (United States) · funded by National Institutes of Health
2018–2024 · research · R44
Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery
Aarash Bordbar · Sinopia Biosciences (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery
Aarash Bordbar · Sinopia Biosciences (United States) · funded by National Institutes of Health
2016–2022 · research · R44
Developing a systems biology platform for predicting, preventing, and treating drug side effects
Aarash Bordbar · Sinopia Biosciences (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Developing a Systems Biology Platform for Predicting Drug Toxicity and Safety
Aarash Bordbar · Sinopia Biosciences (United States) · funded by National Institutes of Health
2016–2021 · research · R44
Developing a systems biology platform for predicting, preventing, and treating drug side effects
Aarash Bordbar · Sinopia Biosciences (United States) · funded by National Institutes of Health
2015–2021 · research · R44
Improving safety and efficacy of platelet transfusion through systems biology
Aarash Bordbar · Sinopia Biosciences (United States) · funded by National Institutes of Health